TG Therapeutics, Inc. (TGTX) on Wednesday reported positive topline results from its Phase 3 ENHANCE study evaluating a single-infusion initiation regimen for BRIUMVI in adults with relapsing forms of multiple sclerosis.
The study achieved its primary endpoint, showing bioequivalent drug exposure between the currently approved dosing schedule of 150 mg on Day 1 and 450 mg on Day 15 and a new consolidated regimen consisting of a single 600 mg infusion on Day 1. The revised approach would remove the need for a second infusion on Day 15.
BRIUMVI is approved in the U.S. for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. The therapy is also approved in several international markets for adults with active RMS.
The company said it plans to submit a supplemental Biologics License Application to the U.S. FDA in the second half of 2026.
TGTX stock gained nearly 2% in pre-market trading after closing at $39.73 on Tuesday.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.